We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
Read MoreHide Full Article
Key Takeaways
BMY reported positive phase III SCOUT-HCM data for Camzyos in adolescents with obstructive HCM.
Camzyos met its main goal, reducing LVOT gradient and improving secondary measures with placebo-like safety.
BMY halted milvexian ACS study, though two other late-stage trials continue with data due in 2026.
Bristol Myers’ (BMY - Free Report) cardiovascular portfolio currently comprises blockbuster drugs Eliquis and Camzyos.
The company recently presented positive results from the late-stage SCOUT-HCM study evaluating Camzyos (mavacamten) in adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first study of a cardiac myosin inhibitor (CMI) in this patient population.
The study met its primary endpoint, showing a statistically significant reduction from baseline in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 versus placebo, demonstrating Camzyos’ effectiveness in alleviating LVOT obstruction.
Camzyos also demonstrated improvements across multiple secondary endpoints at 28 weeks, with a safety profile comparable to placebo.
These positive data support the potential for Camzyos to be the first CMI for the treatment of adolescent oHCM.
We note that Camzyos is currently approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
A potential approval of Camzyos for a broader patient population should boost sales. The drug raked in sales of over $1 billion in 2025, soaring 77% year over year.
BMY’s cardiovascular portfolio also comprises blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) . Eliquis is one of the biggest contributors to the top line.
However, BMY’s cardiovascular portfolio suffered a hit in late 2025 after the company decided to discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.
BMY and partner Johnson & Johnson (JNJ - Free Report) were evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event.
Both companies decided to discontinue the phase III Librexia ACS study following a preplanned interim analysis by the Independent Data Monitoring Committee (“IDMC”), which determined that the study is unlikely to meet the primary efficacy endpoint.
Nonetheless, the IDMC advised that the two other late-stage studies — Librexia AF for atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP) — should proceed as planned. Top-line data from these studies is expected in 2026.
Competition for BMY’s Cardiovascular Drugs
In December 2025, Cytokinetics (CYTK - Free Report) obtained FDA approval for aficamten for the treatment of patients with obstructive HCM in the United States, under the brand name Myqorzo.
This marks the company’s first FDA-approved product, transforming Cytokinetics from a development-stage biotech into a commercial-stage company.
The approval of Myqorzo is a significant boost for CYTK, given the market potential for the oHCM market.
JNJ’s Xarelto is also a Factor Xa inhibitor, similar to Eliquis.
However, JNJ is facing patent challenges for Xarelto in the United States. JNJ co-developed Xarelto with Bayer AG.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have gained 8% year to date against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 9.41x forward earnings, higher than its mean of 8.51x but lower than the large-cap pharma industry’s 16.74x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.26 from $6.24 in the past 30 days, while that for 2027 has increased to $6.09 from $6.05.
View the Zacks #1 Rank List
Image: Shutterstock
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
Key Takeaways
Bristol Myers’ (BMY - Free Report) cardiovascular portfolio currently comprises blockbuster drugs Eliquis and Camzyos.
The company recently presented positive results from the late-stage SCOUT-HCM study evaluating Camzyos (mavacamten) in adolescents aged 12 to under 18 years with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking the first study of a cardiac myosin inhibitor (CMI) in this patient population.
The study met its primary endpoint, showing a statistically significant reduction from baseline in the Valsalva left ventricular outflow tract (LVOT) gradient at week 28 versus placebo, demonstrating Camzyos’ effectiveness in alleviating LVOT obstruction.
Camzyos also demonstrated improvements across multiple secondary endpoints at 28 weeks, with a safety profile comparable to placebo.
These positive data support the potential for Camzyos to be the first CMI for the treatment of adolescent oHCM.
We note that Camzyos is currently approved for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
A potential approval of Camzyos for a broader patient population should boost sales. The drug raked in sales of over $1 billion in 2025, soaring 77% year over year.
BMY’s cardiovascular portfolio also comprises blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer (PFE - Free Report) . Eliquis is one of the biggest contributors to the top line.
However, BMY’s cardiovascular portfolio suffered a hit in late 2025 after the company decided to discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.
BMY and partner Johnson & Johnson (JNJ - Free Report) were evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS) event.
Both companies decided to discontinue the phase III Librexia ACS study following a preplanned interim analysis by the Independent Data Monitoring Committee (“IDMC”), which determined that the study is unlikely to meet the primary efficacy endpoint.
Nonetheless, the IDMC advised that the two other late-stage studies — Librexia AF for atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP) — should proceed as planned. Top-line data from these studies is expected in 2026.
Competition for BMY’s Cardiovascular Drugs
In December 2025, Cytokinetics (CYTK - Free Report) obtained FDA approval for aficamten for the treatment of patients with obstructive HCM in the United States, under the brand name Myqorzo.
This marks the company’s first FDA-approved product, transforming Cytokinetics from a development-stage biotech into a commercial-stage company.
The approval of Myqorzo is a significant boost for CYTK, given the market potential for the oHCM market.
JNJ’s Xarelto is also a Factor Xa inhibitor, similar to Eliquis.
However, JNJ is facing patent challenges for Xarelto in the United States. JNJ co-developed Xarelto with Bayer AG.
BMY’s Price Performance, Valuation & Estimates
Shares of Bristol Myers have gained 8% year to date against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 9.41x forward earnings, higher than its mean of 8.51x but lower than the large-cap pharma industry’s 16.74x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.26 from $6.24 in the past 30 days, while that for 2027 has increased to $6.09 from $6.05.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.